Pay in 4 interest-free payments of $6.09 Learn more
Ships within 48 hours · Estimated delivery Sep 23 - Sep 28
Evidence Snapshot The STEP trials demonstrated significant weight reduction with semaglutide, with gastrointestinal side effects most prominent during dose escalation. Long-term micronutrient outcomes were not primary endpoints
The abdomen (belly) is a popular place to inject
A 15% body weight reduction the STEP-1 semaglutide benchmark is associated with type 2 diabetes remission in 37% of treated patients, 28% reduction in hypertension medication requirements, 25% improvement in sleep apnea severity, and MASH progression reversal
The authors claim that it is the most comprehensive collection of evidence on post-GLP-1RA weight outcomes to date. Weight regain after GLP-1 discontinuation The study searched multiple databases for randomized controlled trials (RCTs), non-randomized interventional studies, and observational studies examining weight trajectories after discontinuing GLP-1RAs
US$ 25.87
US$ 20.94
US$ 26.73
US$ 21.36
US$ 28.07
